NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis $1.07 +0.08 (+7.56%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quince Therapeutics Stock (NASDAQ:QNCX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quince Therapeutics alerts:Sign Up Key Stats Today's Range$0.96▼$1.1150-Day Range$0.80▼$1.8352-Week Range$0.79▼$45.50Volume1.82 million shsAverage Volume2.15 million shsMarket Capitalization$17.44 millionP/E RatioN/ADividend YieldN/APrice Target$65.00Consensus RatingReduce Company Overview Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. Read More Quince Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreQNCX MarketRank™: Quince Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 597th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingQuince Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and 2 sell ratings.Upside PotentialQuince Therapeutics has a consensus price target of $65.00, representing about 5,974.8% upside from its current price of $1.07.Amount of Analyst CoverageQuince Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Quince Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quince Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quince Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.16% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 1.07, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quince Therapeutics has recently decreased by 8.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuince Therapeutics does not currently pay a dividend.Dividend GrowthQuince Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.17 News SentimentQuince Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 28 people have searched for QNCX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quince Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Quince Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions30.75% of the stock of Quince Therapeutics is held by institutions.Read more about Quince Therapeutics' insider trading history. Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Stock News HeadlinesQuince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks TranscriptMay 18 at 7:00 PM | seekingalpha.comUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18 at 10:21 AM | globenewswire.comNobody Understands Why Trump Is Invading Iran (here’s the answer)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18 at 9:26 AM | globenewswire.comQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineMay 18 at 9:26 AM | globenewswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Reduce" from BrokeragesMay 17 at 4:43 AM | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Upgraded at Wall Street ZenMay 17 at 1:07 AM | americanbankingnews.comQuince Therapeutics (QNCX) price target increased by 100.00% to 81.60May 15, 2026 | msn.comSee More Headlines QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed this year? Quince Therapeutics' stock was trading at $33.50 at the start of the year. Since then, QNCX shares have decreased by 96.8% and is now trading at $1.07. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($1.30) by $0.71. When did Quince Therapeutics' stock split? Quince Therapeutics shares reverse split before market open on Monday, April 13th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 12th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Quince Therapeutics IPO? Quince Therapeutics (QNCX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,412,000 shares at $16.00-$18.00 per share. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quince Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include PayPal (PYPL), SoFi Technologies (SOFI), TherapeuticsMD (TXMD), Achilles Therapeutics (ACHL), Agile Therapeutics (AGRX) and Aytu BioPharma (AYTU). Company Calendar Last Earnings5/11/2026Today5/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 QNCX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QNCX Previous SymbolNASDAQ:CRTX CIK1662774 Webwww.quincetx.com Phone(650) 910-5717FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Quince Therapeutics$65.00 High Price Target$80.00 Low Price Target$50.00 Potential Upside/Downside+5,974.8%Consensus RatingReduce Rating Score (0-4)1.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($10.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-372.88% Return on Assets-67.99% Debt Debt-to-Equity RatioN/A Current Ratio2.92 Quick Ratio2.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($6.41) per share Price / Book-0.17Miscellaneous Outstanding Shares16,301,000Free Float13,562,000Market Cap$17.44 million OptionableOptionable Beta1.45 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:QNCX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
